Company

Sirnaomics, Inc.

Sirnaomics develops RNA interference medicines for cancer, liver fibrosis and other conditions.

About

Founded in 2008 and based in Gaithersburg, US, Sirnaomics develops RNA interference medicines, including STP705 and STP707, for oncology, liver fibrosis, anti-fibrotic therapies and viral infection. It also has branches in Suzhou, Guangzhou and Hong Kong. In December 2021, it closed pre-IPO funding from Innoforce Pharmaceuticals Co., Ltd.

5Funding rounds

9Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in